Related Experiment Video
Updated: Jun 13, 2026
Flow Cytometric Characterization of Murine B Cell Development
Published on: January 22, 2021
A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma
Stephanie D Schniederjan1, Shiyong Li, Debra F Saxe
1Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Insights
Distinguishing Burkitt lymphoma (BL) from CD10+ diffuse large B-cell lymphoma (DLBCL) is crucial for treatment. Flow cytometric immunophenotyping revealed lower CD44 and CD54 expression in BL, aiding differential diagnosis.
Area of Science:
- Hematology
- Immunophenotyping
- Oncology
Background:
- Accurate differential diagnosis between Burkitt lymphoma (BL) and CD10+ diffuse large B-cell lymphoma (DLBCL) is critical due to distinct treatment protocols.
- Previous research identified potential differentially expressed antigens between these lymphoma subtypes.
Purpose of the Study:
- To evaluate the utility of specific antigen markers in differentiating BL from CD10+ DLBCL using flow cytometric immunophenotyping (FCI).
Main Methods:
- Multiparameter FCI was conducted on 23 cases of CD10+ B-cell lymphomas (13 BL, 10 CD10+ DLBCL).
- Antibodies used included CD18, CD20, CD43, CD44, and CD54, along with isotype controls.
Main Results:
- Significantly lower expression of CD44 (P = .001) and CD54 (P = .01) was observed in BL compared to CD10+ DLBCL.
- No significant differences in CD18 and CD43 expression were found between the two groups.
Conclusions:
- CD44 and CD54 expression levels are significantly different between BL and CD10+ DLBCL.
- These markers show promise for improving the differential diagnosis of these lymphomas via FCI.
Abstract:
Rapid and accurate differential diagnosis between Burkitt lymphoma (BL) and CD10+ diffuse large B-cell lymphoma (DLBCL) is imperative because their treatment differs. Recent studies have characterized several antigens differentially expressed in these 2 types of lymphoma. Our goal was to determine whether use of these markers would aid in the differential diagnosis of BL vs CD10+ DLBCL by flow cytometric immunophenotyping (FCI). Twenty-three cases of CD10+ B-cell lymphomas with available cryopreserved samples were identified (13 BL and 10 CD10+ DLBCL). Multiparameter FCI was performed using the following antibodies: CD18, CD20, CD43, CD44, and CD54 and isotype controls. Expression of CD44 and CD54 was detected at a significantly lower level in BL compared with CD10+ DLBCL (P = .001 and P = .01, respectively). There was not a significant difference in expression of CD18 and CD43. Our data show that expression of CD44 and CD54 differs significantly between BL and CD10+ DLBCL.
